SCHEMBL65670

SCHEMBL65670

CNS(=O)(=O)C1CCN(C(=O)COc2ccnc3c(C(F)(F)F)cccc23)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
SCD O00767 6/20 0.40
ENPP2 Q13822 4/20 0.40
HPGD P15428 1/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38
RBP4 P02753 1/20 0.37
NCF1 P14598 1/20 0.37
PTK2 Q05397 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
CLK2 P49760 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
CSNK2A1 P68400 1/20 0.36
STK3 Q13188 1/20 0.36
HIPK4 Q8NE63 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL66082 0.90 ENPP2 (0.41) KDM4ESCDENPP2HPGDALDH1A1
SCHEMBL57774 0.88 USP2 (0.44) KDM4ESCDENPP2HPGDALDH1A1
SCHEMBL55921 0.87 KDM4E (0.41) KDM4ESCDENPP2HPGDALDH1A1
SCHEMBL66074 0.87 ALDH1A1 (0.42) KDM4ESCDENPP2HPGDALDH1A1
SCHEMBL65756 0.84 ALDH1A1 (0.40) KDM4EENPP2HPGDALDH1A1MAPT
SCHEMBL66515 0.83 USP2 (0.41) SCDENPP2ALDH1A1RBP4
SCHEMBL14683241 0.76 ENPP2 (0.53) KDM4EENPP2HPGDALDH1A1MAPT
SCHEMBL2626334 0.76 SCN9A (0.42)
SCHEMBL15393601 0.74 ENPP2 (0.52) KDM4EENPP2HPGDALDH1A1MAPT
SCHEMBL12718831 0.74 ENPP2 (0.51) KDM4EENPP2HPGDALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129546-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-06 US disclosed
US-8129546-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-06 US disclosed
US-20110077269-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-31 US disclosed
US-20110077269-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-31 US disclosed
US-7842819-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-30 US disclosed
US-7842819-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-30 US disclosed
US-20070203122-A1 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-08-30 US disclosed
US-20070203122-A1 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203122-A1 Derivatives for modulation of ion channels TRPV1, TRPA1, TRPV2 KDM4E 3285/4885SCD 1540/4885ENPP2 463/4885
US-20110077269-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS TRPV1, TRPA1, TRPV2 KDM4E 3285/4885SCD 1540/4885ENPP2 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.